Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of Mississippi Medical Center |
---|---|
Information provided by: | University of Mississippi Medical Center |
ClinicalTrials.gov Identifier: | NCT00830765 |
Preterm birth is the most common and costly complication in obstetrics. It complicates up to 11 % of all pregnancies and it is responsible for 70% of sick babies. Recently two studies have shown that giving progesterone (a normal hormone made by the ovaries) prolongs gestation in women who have had a preterm birth in an earlier pregnancy (and therefore are at risk for another early delivery). There are other studies that show that this technique of giving a weekly shot of progesterone does not prevent preterm birth. In addition, There are other groups of patients who are at very high risk for preterm birth which have not been studied. They include: 1.) Cervical cerclage (a stitch in the mouth of the womb); 2.) Multifetal gestation (twins, triplets, etc.); 3.) Women with preterm (<34 weeks) rupture of the membranes; 4.) Women with preterm labor during the current pregnancy with intact membranes who have been tocolyzed (have their labor stopped and are getting ready to go home). We purpose to give weekly shots of progesterone or a placebo in a randomized fashion to women in the first group who are at risk for preterm delivery due to an early birth in a previous pregnancy as well as the other four groups listed. If progesterone given weekly is successful at preventing early delivery as compared to the placebo group then great benefit for these women as well as future pregnancies would be accrued.
Condition | Intervention |
---|---|
Preterm Birth |
Drug: Progesterone (OHP17) Drug: Placebo |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment |
Official Title: | The Use of Progesterone to Reduce Preterm Birth |
Enrollment: | 139 |
Study Start Date: | June 2004 |
Estimated Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1 Placebo: Placebo Comparator
The participant will receive a weekly injection of placebo from the time of enrollment up until 34 weeks' gestation or delivery, whichever occurs first.
|
Drug: Placebo
2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
|
Progesterone: Active Comparator
The participant will receive weekly injections of 100mg of OHP17 from the time of enrollment until 34 weeks' gestation or delivery, whichever occurs first.
|
Drug: Progesterone (OHP17)
100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.
|
Ages Eligible for Study: | 16 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Mississippi | |
Winfred L Wiser Hospital for Women and Infants at the University of Mississippi Medical Center | |
Jackson, Mississippi, United States, 39216 |
Principal Investigator: | John C Morrison, MD | University of Mississippi Medical Center |
Responsible Party: | University of Mississippi Medical Center ( John C Morrison, MD ) |
Study ID Numbers: | 2003-0239 |
Study First Received: | December 16, 2008 |
Last Updated: | January 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00830765 History of Changes |
Health Authority: | United States: Institutional Review Board |
Pregnancy Complications Progesterone Hormone Antagonists Progestins Obstetric Labor, Premature |
Hormones, Hormone Substitutes, and Hormone Antagonists Obstetric Labor Complications Hormones Premature Birth |
Pregnancy Complications Progesterone Progestins Obstetric Labor, Premature Physiological Effects of Drugs |
Hormones, Hormone Substitutes, and Hormone Antagonists Obstetric Labor Complications Hormones Pharmacologic Actions Premature Birth |